AbbVie, Merck KGaA, and CytomX are racing to bring ADCs into late-line CRC. I’ve pulled together a few notes from my own work on what’s happening and what comes next.
Nazli A. Guner retweeted
Happy #JefferiesHealthcare to all who celebrate
NEW from @FT: Johnson & Johnson is poised to buy privately held eye disease drug developer Ollin Biosciences for up to $3.4bn, the latest in a glut of bolt-on acquisitions in the biotechnology sector.
Nazli A. Guner retweeted
FDA rejects Summit Therapeutics’ ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class fiercepharma.com/pharma/fda-…
Nazli A. Guner retweeted
can we systematically identify drugs that reverse specific hallmarks of aging?
a nature aging study mapped 2,358 longevity-associated genes onto the human interactome and evaluated 6,442 compounds.
network biology + transcriptional signatures offer an interesting framework for longevity drug discovery.
nature.com/articles/s43587-0…
Nazli A. Guner retweeted
Oveporexton (Orexin 2 agonist) Part 1- The privileged scaffold is the Pyrrolidine core. It The ring features two contiguous defined stereocenters at 3 2S, 3R. This rigid 3D spatial alignment is highly optimized to precisely match the contours of the OX2 receptor binding pocket.
Nazli A. Guner retweeted
🇨🇳Huadong Medicine’s DR10624 (FGF21R/GCGR/GLP-1R triple agonist) shows strong Phase 2 data in MASLD/MASH at #AASLD2026
Late-breaking oral presentation of the China Phase 2 DR10624-202 study (weekly SC for 12 weeks).
Key efficacy (Week 12):
- 50 mg: 80.3% relative reduction in liver fat content (LFC) vs baseline
- 94.1% of patients achieved ≥50% LFC reduction; 87.7% achieved ≥70%
- 81.8% of patients in 50 mg group normalized liver fat (LFC <5%; baseline mean 19.7%)
- Significant LFC reduction already seen by Week 6
- 70.4% of patients in 25 mg group achieved ≥30% reduction in liver stiffness (LSM)
- Improvements in FIB-4, APRI, FAST, ALT, AST, ALP, GGT
- Favorable changes in lipids (TG, TC, non-HDL-C, LDL-C, VLDL-C, ApoB), adiponectin ↑, uric acid and body weight ↓
Nazli A. Guner retweeted
Replying to @altcap
Brad I do! Biotech + AI will be powerful to speed candidates forward, increase enrollment speed in RCTs and, maybe the boring but vital part, fix the last mile problems in healthcare. That last part seems most tractable, consumers detest waiting in offices, want to have reliable access to digital advice and diagnostics and health care financing is a consumer crisis. These problems most closely resemble the breakthroughs and productivity gains tech has brought in customer service and fintech - and need more hype not less IMO.
Do you know what our industry’s missing piece is? Marketing.
Tech marketed itself for years. Now it’s so excited about biology that it’s just waiting for a wink from us. So why do we keep focusing on what’s wrong and what won’t work?
Lead them, not by overselling, but by telling the truth about what the science can do.
Even our everyday work is enough to get them excited.
5
683
Nazli A. Guner retweeted
Replying to @drrichjlaw @AAMortazavi
Let's just run thru a few drug industry assumptions...
40% of new drug approvals in 2026 were first-in-class (FDA data)
Novel biology is generally riskier, so have to assume more than 40% of the INDs are first-in-class (well accepted)
1200 INDs from commercial sponsors last year (FDA data)
70%+ of initial clinical starts last year were from R&D stage biotechs, private and public (IQVIA data)
Implies at least ~500 were for first-in-class programs from biotech companies.
With preclinical failure rates, 500 INDs would require about 800 Development Candidates
800 DCs probably require 2000 new hit-finding discovery programs.
So you really think starting and funding 2000 discovery campaigns is only 1% of biotech invested capital?
The math just doesn't compute.
I suspect it's easily more like 20-30% of biotech invested capital today.
Since $25B has gone into biotech equity financings this year, that's at least $5-8B into first in class programs..
But we both agree that whatever it is, it should be an even larger proportion of industry activity!
Nazli A. Guner retweeted
Josep Llovet, MD, discusses unmet needs in HCC detection and management during #LiverCancerAwarenessMonth. #oncology
See our gastrointestinal cancers page for more insights: onclive.com/clinical/gastroi…
Nazli A. Guner retweeted
New @RelationRx blog post: The case for better osteoporosis therapies
relationrx.substack.com/p/th…
A new atlas of colorectal tumors sheds light on why cancers in young people are more dangerous. trib.al/mFXrjq2
Nazli A. Guner retweeted
#ESMO26 is a wrap. A few thoughts.
It is a privilege to be an oncologist. To everyone who took the time to meet with me, lend their expertise or mentor me in some way: thank you. I am grateful. Also, to the patients who contributed their time, hope and lives to allow these studies to happen, thank you. This is what allows progress.
1. ESMO absolutely brought incredible advancements. So did China. This was the first global conference where the USA has clearly been dethroned as the de facto biomedical trial leader (5 of the 7 Presidential Symposium late-breakers focused on new drugs were Chinese developed). Chinese patients will be getting access to the latest biomedical advances, first.
2. The molecular era is here for KRAS. Expect it to come to early lines, in every tumor, fast. Expect sexy combos. (I am personally very excited about Genmab + Incyte's LGR5-EGFR + G12D but also think Verastem’s and RevMed’s G12D’s look great.)
3. Some advances look meaningful but are minor. PD1-VEGF beats PD1, but it wasn't compared to PD1 + VEGF. The benefit looks similar to adding bev (duh).
4. Cellular therapy is finally here for solid tumors. Get your systems ready now, it takes years to truly prepare. The 66% response rate for TezR (SL-28) across all-comer solid tumors blew my mind.
5. ADCs will hit CRC/GI quickly, and in a few years there will be many questions about sequencing. Please please please stop using the same payloads.
6. Medical education is more important than ever with how fast the field is moving. If anyone has advice on how @TheGutOncLab can disseminate information better (like the people at @OpenMedicineHQ and @OncoAlert do), please let me know.
Here's to next year. Already getting ready for @ASCO GI
@TheGutOncLab @Onco_Nexus
Nazli A. Guner retweeted
A bold call @myESMO from @BarbaraPistill2 for trials that compare existing ADCs against new, emerging ADCs to see if there are truly any differences (as opposed to new ADCS vs old chemotherapy). Will be interesting to see which companies believe so much in their product that they step forward to that challenge.
Nazli A. Guner retweeted
$GILD to Acquire 🇨🇳PepStar’s Oral IL-23R Inhibitor Program for $1.275B Upfront, Adding a New Asset to Its IBD Pipeline
Lead candidate HCXT-2001: an oral macrocyclic peptide targeting IL-23R
Deal terms
- Upfront payment: $1.275 billion in cash, subject to customary adjustments.
- Rights acquired: Worldwide rights to the oral IL-23R inhibitor program, including HCXT-2001.
- Expected closing: Q4 2026, subject to customary closing conditions.
Founded in Shanghai in 2023, PepStar Therapeutics focuses on developing novel peptide therapeutics, with programs covering solid tumors, autoimmune diseases, allergies and inflammatory conditions.
Founder and CEO Haibing Guo previously worked at Novartis and J&J on innovative drug research in areas including oncology and liver fibrosis. In 2017, he joined 🇨🇳Jemincare, where he served as head of R&D, chief scientific officer and group vice president.
PepStar’s core technology focus is oral macrocyclic peptides with extended half-lives.
Nazli A. Guner retweeted
ADC dealmaking remains active in 2026, with median upfront payments rising sharply even as overall deal volume remains below 2025.
Find additional biopharma deal data and charts on DealForma.
Nazli A. Guner retweeted
The benifit is same as if you give neo adjuvant pembrolizumab? - cross trial comparisons-
Will this hold true if Pembrolizumab is given neoadjuvant in control arm ?
We don't know. @OncBrothers @OncoAlert @myESMO #esmo26
🚨 ESMO 2026 | INTErpath-001 (LBA1) - as data is released by Esmo
🔹 24-month RFS: 82.2% vs 70.0%
HR 0.58 (95% CI 0.45–0.75); P<0.001
🔹 24-month DMFS: 88.5% vs 80.2%
HR 0.62 (95% CI 0.45–0.85); P=0.002
🔹 Grade ≥3 adverse events: 23.6% vs 20.3%
The trial randomized 1,137 patients with resected stage IIB–IV melanoma. Both arms received pembrolizumab; the experimental arm added an individualized mRNA neoantigen therapy.
The key question now: will better recurrence control translate into an overall survival benefit?
Looking forward to full dataset on day 2 .
#ESMO26 @myESMO

































